Nasdaq
$21.01▲ 2.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.12BShares out 53.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 8.5Pre-market26.08.05 21:06SCHEDULE 13GOwnership#●●●#●●●
Seaport Therapeutics, Inc.Bullish
Seaport Therapeutics, Inc.에 대해 Zohar Daphne가 2026년 8월 5일자로 Schedule 13G 공시를 통해 대량 지분 보유 사실을 신고했습니다. 이는 특정 투자자가 해당 기업의 지분을 5% 이상 확보하여 주요 주주가 되었음을 의미합니다.…more
$21.01+2.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.5Pre-market26.08.05 19:01SCHEDULE 13GOwnership
Seaport Therapeutics, Inc.
Paul Steven M은 2026년 8월 5일 공시를 통해 Seaport Therapeutics, Inc.에 대한 대량 지분 보유 현황을 Schedule 13G로 보고하였습니다. 이는 특정 투자자가 해당 기업의 지분을 5% 이상 확보했음을 의미하며, 향후 경영권이나 주가에 영향을 미칠 수 있는 주요 지분 변동 사항입니다.…more
$21.01+2.04%vs prev closeView filingShare - 8.3Pre-market26.08.03 20:1110-QEarnings
Seaport Therapeutics, Inc.
Seaport Therapeutics는 2026년 6월 30일로 종료된 분기에 대한 10-Q 보고서를 제출하였습니다. 해당 보고서는 회사의 재무 상태와 운영 결과를 포함하고 있으며, 최고경영자 Daphne Zohar와 최고재무책임자 Lauren White가 재무제표의 정확성과 내부 통제 절차의 유효성을 인증하였습니다.…more
$21.01+2.04%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 20:22#●●●#●●●#●●●
Seaport Therapeutics Presents Phase 1 Clinical Data for GlyphAgo
Seaport Therapeutics presented Phase 1 data for GlyphAgo at the ECNP Congress, demonstrating improved bioavailability and reduced pharmacokinetic variability. The company is now advancing the drug into Phase 2 and Phase 2/3 trials for generalized anxiety disorder.…more
$21.01+2.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.7Pre-market26.10.07 20:08
●●●●●●●● ●●●●● ●●●●●●
Seaport Therapeutics has initiated the first patient dosing in its Phase 2a clinical trial for the generalized anxiety disorder treatment, GlyphAgo. Topline data from the study is expected to be released in early 2028.…more
$21.01+2.04%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 20:12
●●●●●●●● ●●●●● ●●●●●●
Seaport Therapeutics reported that its drug candidate GlyphAllo met primary and secondary endpoints in a Phase 1 trial, showing no impairment to driving performance. The company plans to submit these results to the FDA to support its ongoing development program.…more
$21.01+2.04%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report